Although the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) is frequently used to estimate cardiovascular risk among rheumatoid arthritis (RA) patients, it does not include plasma C-reactive protein (CRP) concentrations. The study by Erre and colleagues revealed that a 20 mg/L increase in CRP concentrations was correlated with a 1% increase in 10-year cardiovascular risk among RA patients [1]. Their findings suggest that aggressive treatment aimed at reducing inflammation may decrease cardiovascular risks.
